What To Expect at the Largest Gathering of LNP Experts?
As the LNP field continues to expand, from mRNA vaccines to cutting-edge cell and gene therapies, the 5th LNP Formulation & Process Development Summit returns to Boston in April 2026. Curated in collaboration our Scientific Advisory Board, Annette Bak (AstraZeneca), Luis Brito (Beam Therapeutics), and Ching Kim Tye (Sanofi), this premier forum is designed to deliver LNP-specific networking and knowledge sharing.
Join LNP innovators to advance extrahepatic targeting, stable formulation design, robust analytical characterization, and consistent large-scale manufacturing to accelerate LNP-based therapeutics to the market.
Unmissable Agenda Highlights
Attracting Investment & Acquisition Opportunities
Amid a surge of high-value deals across the LNP landscape, Capstan Therapeutics, GV and Chiesi Global Rare Diseases are joining a strategic panel to unpack the motivations driving recent acquisitions and partnerships within the LNP community.
Achieving Extrahepatic Targeting with LNPs
Discover ground-breaking approaches in targeted delivery and innovative formulations enabling extrahepatic applications. Alnylam, Servier and Novartis will share insights to unlock new therapeutic opportunities across diverse disease areas.
LNPs for Cell & Gene Therapy Delivery
Explore pioneering work on LNP development for cell therapy and gene editing payloads. Brand-new speakers from Yoltech Therapeutics, Innorna and Corner Therapeutics will share their recent work shaping the next generation of cell and gene therapies.
Interactive LNP-Focused Workshop Day
Take part in 4 deep dive workshops dedicated to solving key challenges in LNP screening, targeted LNP analytics, brain and muscle delivery, and overcoming immunogenicity. Led by experts from Novo Nordisk, GSK, Editas Medicines, and more, this day offers practical insights to overcome bottlenecks in LNP development.
Gain a Refresher on LNP Core Principles
The LNP 101 day is returning in 2026 to provide a foundation on LNP formulation, biology and manufacturing. Learn from Land Therapeutics, Beam Therapeutics and Arbor Biotechnology and ensure you have a robust understanding of end-to-end LNP development.
Formulating Thermostable LNPs
As storage and thermostability of LNPs remains a tough challenge, hear how Eli Lilly & Co and AstraZeneca are leveraging strategies such as lyophilization and buffer optimization to improve LNP stability and shelf-life.
Divide & Conquer
The LNP field is vast, which is why we have meticulously researched with subject matter experts to identify the key challenges facing the community across the drug development pipeline.
By splitting into 3 end-to-end tracks (Analytical Development & Characterization, Formulation & Delivery and Process Development & Manufacturing), our speakers have tailored their presentations to dive into specific challenges for those aspects of development.
Send different members of your team across the three content streams to ensure you gain a comprehensive understanding of the entire LNP development pipeline, from early formulation through to commercial-scale production, and return equipped with the insights needed to accelerate your LNP-mediated medicines.
Analytical Development & Characterization
- Molecular Characterization of Lipid Nanoparticles & mRNA Packaging with Single Particle Charge Detection Mass Spectrometry
Evan Williams, Professor, University of California, Berkeley
- De-Risking LNP Stability through Advanced Analytical Strategies to Monitor Degradation & Optimize Shelf-Life
Isabelle Gusev, Principal Scientist & Group Leader, Analytical Development, CMC, Tessera Therapeutics
- Employing High Throughput, Semi-Automated Analytical Strategies to Accelerate LNP Formulation Optimization
Natalya Martin, Principal Scientist, Biochemistry & Biophysics, Analytical Development, Sanofi
Formulation & Delivery
- Engineering LNPs to Detarget the Liver by Balancing Circulation Time & Targetability for More Efficacious Drug Products
Amit Singh, Director, Delivery Discovery, Mote Therapeutics
- In Vivo Genome Editing: Translating Science from Bench to Bedside
Emma Wang, Chief Technology Officer, YolTech Therapeutics
- An ‘Irrational’ Ionizable Lipid Design Approach Based on Machine Learning Models
Bo Ying, Chief Executive Officer, Abogen Biosciences
Process Development & Manufacturing
- Refining Lyophilization Processes to Preserve LNP Quality & Morphology for Enhanced Stability & Shelf-Life
Liping Zhou, Senior Director, Advanced Drug Delivery, AstraZeneca
- Optimizing TFF by Incorporating Membrane Screening & In-Process Analytics to Enhance Buffer Exchange & Concentration
Matthew Reynolds-Tejeda, Senior Associate Scientist, Nanoparticle Process Development, Strand Therapeutics
- mRNA-LNP Product Development: Providing a Roadmap to Advance from Preclinical Research to Commercialization
Brenda Star Clemente, Director, Drug Product Process Development, Arcturus Therapeutics
Explore the Full Event Guide
- 50+ Data-Driven Case Studies on LNP Development for mRNA Vaccines, Cell Therapies, Gene Editing Payloads & Beyond
- 8+ Hours of Dedicated Networking to Connect with Fellow LNP Peers
- 3 Tracks of End-to-End Scientific Insights: Analytical Development & Characterization, Formulation & Delivery & Process Development & Manufacturing
- 3 Leading Scientific Advisory Board Members from AstraZeneca, Beam Therapeutics & Sanofi
- The World’s Largest LNP-Dedicated Forum
Attending Companies Include
Explore the Agenda
Discover the latest breakthroughs shaping LNP discovery, formulation, analytics, and manufacturing. Gain exclusive insights from industry leaders during data-driven presentations, interactive roundtables, and expert panel discussions.
Partner With Us
Showcase your offerings alongside other leading solution providers to a community dedicated to cutting-edge LNP innovation. Position your brand at the heart of the biopharma deals and partnerships defining RNA, cell, and gene therapy pipelines.
Join LNP Experts
Connect with LNP innovators, from across the globe and engage in the hottest conversations spanning the end-to-end development of LNP drug products. During the dedicated networking sessions, make critical connections and build meaningful collaborations.